Durable Songjiang rubber expansion joint contract for Astrazeneca pharmaceutical factory

Shanghai Songjiang Group introduces the durable Songjiang rubber expansion joint contract for Astrazeneca pharmaceutical factory .Shanghai Songjiang Group specializes in providing pharmaceutical factory molded rubber expansion joint products for pharmaceutical factories. Our customers get everything they need from us to carry out their projects in an optimum way.

I. Introduction to Astrazeneca pharmaceutical factory:

1. Astrazeneca is an innovation-driven global biopharmaceutical company focused on the development, manufacture, and distribution of prescription medicines that are bringing profound change to the healthcare industry.
2. Research and patients are our top priorities, and our expertise and resources are focused on the areas of disease where we believe we can make the most difference. We focus on oncology, cardiovascular/metabolic, respiratory/inflammatory/autoimmune, and other therapeutic areas. In addition, we are actively exploring cooperation opportunities in the fields of anti-infection and neuroscience.
3. Delivering medicines to patients through innovative research and global commercialization excellence is the path to strategic success.
4. In addition to our research and development projects, we constantly seek opportunities to collaborate with leading scientific institutions to accelerate the development of new drugs. In recent years, we have actively expanded early-stage biotechnology and academic collaborations and strengthened our product line through licensing and acquisitions to provide physicians and patients with a broader range of treatment options.
Cooperation is part of our daily work. Understanding the needs of patients and healthcare professionals, and understanding the perspectives of regulators and health service payers, are critical to our success. We work closely with these communities, drawing on their insights to develop unique targeted drugs that will make a difference in the healthcare industry.
6. We are committed to social responsibility while promoting business success, integrating integrity and high ethical standards into our daily work to maintain the trust of our stakeholders.
7. Improving health is one of the most challenging issues facing the world today, and promoting development in this area will require enormous long-term efforts. AstraZeneca is committed to making an important contribution to this goal.

Ii. AstraZeneca Pharmaceutical Company Profile:
1. Astrazeneca is an innovation-driven global integrated biopharmaceutical company. We are focused on expanding the frontiers of science and developing life-changing drugs.
2. Astrazeneca is headquartered in London and employs 57,500 people worldwide. We have 22 production and supply bases in 16 countries, and our products are sold in more than 100 countries and regions around the world. In 2014, global sales reached 26.1 billion US dollars.
3. To address future medical needs, we must actively explore uncharted territory. AstraZeneca invests more than $4.9 billion a year in research and development. Backed by strong technology and innovation, AstraZeneca continues to develop new drugs, ensuring that we remain at the forefront of human disease research.
4. The Asia Pacific market is an important part of Astrazeneca’s business growth and global layout, and China plays an important role in the Asia Pacific business development strategy. AstraZeneca’s sales in China exceeded $2.2 billion in 2014.
5. As the future development command center, product research and development center, and market supply center in The Asia-pacific region, AstraZeneca is continuously increasing its investment in China. AstraZeneca spent $300 million in 2012 to build its second supply base in China, following its $290 million Wuxi supply base, in Taizhou China Pharmaceutical City, which began commercial operation in October 2014.
6. AstraZeneca Wuxi Supply Base is located in Wuxi New District, Jiangsu Province. The supply base covers an area of 96,000 square meters with a floor area of 58,000 square meters and was officially put into operation in April 2001.
7. AstraZeneca Wuxi Supply Base has world-class production facilities, a modern high-tech modular injection plant, a well-equipped laboratory, a safe and reliable elevated automatic warehouse, and stable and perfect public works facilities. The supply base has passed the GMP certification of China, the European Union, Australia, Brazil, Sudan, and Argentina. We supply cardiovascular, digestive, respiratory, central nervous system, oncology, and anti-infection therapy products.
8. Wuxi Supply base adopts AstraZeneca’s global uniform quality standards, and gradually becomes one of the most important supply bases in AstraZeneca’s supply network with lean and efficient advantages.
9. AstraZeneca attaches great importance to corporate social responsibility and is committed to making positive contributions to Wuxi’s economic and social development. AstraZeneca has been awarded the “Outstanding Foreign Invested Enterprise Award” by Wuxi Municipal Government and Wuxi New District Management Committee many times over the years. From 2001 to 2014, it has paid a total of 7.4 billion YUAN in tax revenue and won the “Tax Contribution Award” issued by Wuxi Municipal Government and Wuxi New District many times. In addition, AstraZeneca has also been awarded “National Pharmaceutical Industry Drug Quality Integrity Construction Model Enterprise” by China Pharmaceutical Quality Management Association for its outstanding performance.
10. Adhering to the five core values of “Science first”, “Patients First”, “Win”, “win” and “forge ahead”, every AstraZeneca employee is constantly exploring the scientific realm and developing life-changing drugs.

2. Introduction to the contract of [Astrazeneca pharmaceutical factory] Shanghai Songjiang Group Long life molded rubber expansion joint on September 23, 2014:

3. Introduction of [Astrazeneca pharmaceutical factory] Shanghai Songjiang Group Long life molded rubber expansion joint:

A molded rubber expansion joint is a flexible connector fabricated of natural or synthetic elastomers and fabric. molded rubber expansion joint offers flexibility allowing concurrent movements, isolation of vibration, reduction of noise, resistance to abrasion, and chemical erosion within fluid systems. If necessary, internal metallic reinforcements are designed to provide stress relief in piping systems due to thermal movements and mechanical vibration.
Angular movement of the Molded rubber expansion joint is possible. The angular joints regulate a defined angular movement, absorb axial reaction force and relieve the pressure on the pipe’s fixed points.

Related links：KXT DN25 Single sphere Non Metal Expansion Joint application for pressure water supply equipment